Gastroesophageal Junction Adenocarcinoma

subtype

Identifier: CI-CAN-00005403
Entity page: /cancer/gastroesophageal-junction-adenocarcinoma ↗
Edges: 1,199

Neighbours: 15 genes18 drugs10 trials
Drawn: 43 of 43 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Gastroesophageal Junction Adenocarcinoma approved for …APPROVED_FOR17 of 13
← approved for	Trastuzumabmonoclonal_antibody 3 source records aggregated	supports	FDA ORIG	Gastroesophageal Junction Adenocarcinoma	3	Regulatory	openfda	graph →
← approved for	Durvalumabmonoclonal_antibody

Gastroesophageal Junction Adenocarcinoma altered in cohorts of …ALTERED_INderived15 of 384show all (up to 200)
← altered in cohorts of	FER1L6 299 / 443 cases (67 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MYC 296 / 443 cases (67 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	POU5F1B 294 / 443 cases (66 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ASAP1 293 / 443 cases (66 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	DDX27 292 / 443 cases (66 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	COL14A1 290 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ZNF831 290 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	GSDMC 289 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	NFATC2 289 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ANXA13 288 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	KLHL38 288 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	WASHC5 288 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ATAD2 287 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	EXT1 287 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	FAM91A1 287 / 443 cases (65 %) · ssm · TCGA-STAD	—	—	Gastric Adenocarcinoma	1	Observed	gdc	graph →

Gastroesophageal Junction Adenocarcinoma altered in cohorts of …ALTERED_INderived15 of 384show all (up to 200)

← altered in cohorts of

FER1L6

299 / 443 cases (67 %) · ssm · TCGA-STAD

—

Gastric Adenocarcinoma

Observed

Gastroesophageal Junction Adenocarcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 107show all (up to 200)
→ investigated in trials for	Oxaliplatinsmall molecule 85 trials (41 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Adenocarcinoma	85	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 77 trials (31 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Adenocarcinoma	77	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 56 trials (28 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Adenocarcinoma	56	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall_molecule 55 trials (31 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Adenocarcinoma	55	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 52 trials (19 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Adenocarcinoma	52	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 44 trials (19 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Adenocarcinoma	44	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 36 trials (14 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Adenocarcinoma	36	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 33 trials (10 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Adenocarcinoma	33	Observed	clinicaltrials	graph →
→ investigated in trials for	Trastuzumabmonoclonal_antibody 28 trials (16 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Adenocarcinoma	28	Observed	clinicaltrials	graph →
→ investigated in trials for	Ramucirumabmonoclonal antibody 26 trials (10 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Adenocarcinoma	26	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 25 trials (9 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Adenocarcinoma	25	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 25 trials (16 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Adenocarcinoma	25	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 19 trials (8 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Adenocarcinoma	19	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal_antibody 10 trials (5 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Adenocarcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Tislelizumabmonoclonal antibody 10 trials (8 active) · roll-up of the cancer and its descendants	—	—	Gastroesophageal Junction Adenocarcinoma	10	Observed	clinicaltrials	graph →

Gastroesophageal Junction Adenocarcinoma studied in …STUDIED_INderived10 of 695show all (up to 200)
→ studied in	NCT03030404completed Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer · condition mapped ALIAS · 695 trials mapped (280 active)	—	—	Hereditary Gastric Diffuse Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05965999recruiting Lucid Registry Study · condition mapped ONTOLOGY_EXACT · 695 trials mapped (280 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07277413Phase 1 · recruiting A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 695 trials mapped (280 active)	—	—	Gastric Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07392892Phase 2/Phase 3 · recruiting Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · condition mapped ONTOLOGY_EXACT · 695 trials mapped (280 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06005493Phase 1/Phase 2 · recruiting Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors · condition mapped ONTOLOGY_EXACT · 695 trials mapped (280 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06203600Phase 2/Phase 3 · recruiting Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial · condition mapped CURATED_BROADER · 695 trials mapped (280 active)	—	—	Gastroesophageal Junction Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05152147Phase 3 · active not recruiting A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers · condition mapped ONTOLOGY_EXACT · 695 trials mapped (280 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06047379Phase 1/Phase 2 · recruiting Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis · condition mapped ONTOLOGY_EXACT · 695 trials mapped (280 active)	—	—	Gastroesophageal Junction Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06123338Phase 2 · recruiting A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer · condition mapped ONTOLOGY_EXACT · 695 trials mapped (280 active)	—	—	Gastric Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06253650Phase 2 · recruiting Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease · condition mapped ALIAS · 695 trials mapped (280 active)	—	—	HER2-Positive Gastric Adenocarcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains